The collaboration philosophy at STSI is highly entrepreneurial with a focus on building sustainable relationships that leverage the expertise and resources of the partners in the relationship and to facilitate projects that lead to the mutual benefit of the parties as well as the advancement of translational medicine and science.
STSI is situated in the heart of San Diego’s life sciences cluster, one of the nation’s most entrepreneurial and successful academic-industry bioscience hubs. In addition to research excellence, the San Diego life science community is known for its collaborative spirit and willingness to take risks to bring new medicines and other therapies to patients.
While many of its collaborations are local, STSI and its researchers also collaborate with many commercial enterprises and academic institutions on a national and international basis. Several fellow recipients of the NIH Clinical and Translational Science Award (CTSA) are among STSI’s collaborators.
Relationships with industry and academic organizations benefit STSI by providing additional sources of funding; and access to technologies including those undergoing commercial development and to knowledge/know-how and/or data that support and expand the institute’s overall research activities. Many collaborations include reciprocal access to collections of research samples and trial results and other resources needed for research on the genetics of cardiovascular disease, metabolic diseases, cancer and other diseases.
STSI’s most important relationship is the collaboration that led to its formation. STSI is the research bridge between Scripps Health, recently named by Thompson Reuters as one of the top 10 health care delivery systems in the U.S., and The Scripps Research Institute (TSRI), the world’s largest independent non-profit biomedical research facility. As the bridge between these two organizations, STSI enjoys a tremendous amount of intellectual rapport from both a basic research perspective and, more uniquely, from a comprehensive clinical perspective.
|Pacific Biosciences||Next gen sequencing|
|Life Technologies||Sample prep for sequencing|
|Prognosys Biosciences||Sequencing tumor|
|Complete Genomics||Next gen sequencing|
|Raindance Technologies||Sample prep for sequencing|
|Regulus Therapeutics||miRNA for CV therapeutics|
|Gen-Probe||Fusion genes in cancer|
|Agilent||Sample prep for sequencing|
|Sangamo Biosciences||Genome editing with engineered zinc finger nucleases|
|The Medicines Company||Anti-platelet clinical trial|
|Navigenics, Microsoft & Affymetrix||Clinical assessment of genome scans (Scripps Genomic Health Initiative)|
|HUYA Biosciences||Atrial fibrillation drug|
|Portola Pharmaceuticals||Anti-platelet clinical trial using genotyping|
|Medtronic||Prediction of ICD need|
|CardioDx||Prediction of vulnerable plaque|
|Johnson & Johnson||Circulating endothelial cells research|
|Accumetrics||Clinical trial of individualized dosing|
|WebMD||Educating physicians on genomic medicine|
|GE Healthcare||Wireless medicine|
|Quest Diagnostics||Circulating endothelial cells research|
|Molecular Response||Molecular markers to predict patient's response to drug|
|Oregon Health Sciences University||Wellderly, genomics of aging & sarcopenia|
|University of California, San Francisco||Wellderly & genomics of osteopenia|
|University of Utah||Genomics of atrial fibrillation|
|University of Pennsylvania (Children's Hospital of Pennsylvania)||Neuroblastoma|
|UC San Diego:||Epigenomics & Alzheimer’s disease|